Generalized myasthenia gravis (gMG) is a complex autoimmune disease with a wide range of symptoms, from ocular issues to severe muscle weakness. As our understanding of the pathophysiology behind gMG evolves, so does our ability to improve patient management. Join Dr. Henry Kaminski as he examines emerging advancements in gMG treatment, including FcRN inhibitors and immune-targeting therapies. Dr. Kaminski is the Meta A. Neumann Professor of Neurology at the George Washington University School of Medicine and Health Sciences.